All In Biotech

NDA 050671 · Baxter Hlthcare

Vancomycin Hydrochloride In Plastic Container

Vancomycin Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Apr 29, 1993

Approved uses

2

Original approval plus efficacy supplements

Registered trials

501

123 Phase 3, 64 recruiting

FAERS reports

7,339

6,612 serious, 1,453 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 9, 2026.

Vancomycin Injection is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: • Septicemia ( 1.1 ) • Infective Endocarditis ( 1.2 ) • Skin and Skin Structure Infections ( 1.3 ) • Bone Infections ( 1.4 ) • Lower Respiratory Tract Infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Injection and other antibacterial drugs, Vancomycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Septicemia Vancomycin Injection is indicated in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2) and Use in Specific Populations (8.4) ] for the treatment of septicemia due to: • Susceptible isolates of methicillin-resistant Staphylococcus aureus (MRSA) and coagulase negative staphylococci. • Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.2 Infective Endocarditis Vancomycin Injection is indicated in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2) and Use in Specific Populations (8.4) ] for the treatment of infective endocarditis due to: • Susceptible isolates of MRSA. • Viridans group streptococci or Streptococcus gallolyticus (previously known as Streptococcus bovis ) and Enterococcus species and Corynebacterium species. For enterococcal endocarditis ( e.g., E. faecalis ), use Vancomycin Injection in...

Mechanism: Vancomycin is an antibacterial drug [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 8, 1998 Supplement 2 · Efficacy Review
  • Apr 29, 1993 Original approval · Type 3 - New Dosage Form Label
5 products under this application
  • VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER · VANCOMYCIN HYDROCHLORIDE EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER · VANCOMYCIN HYDROCHLORIDE EQ 1GM BASE/200ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER · VANCOMYCIN HYDROCHLORIDE EQ 500MG BASE/100ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER · VANCOMYCIN HYDROCHLORIDE EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER · VANCOMYCIN HYDROCHLORIDE EQ 750MG BASE/150ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective850
  • acute kidney injury498
  • off label use460
  • pyrexia433
  • rash309
  • drug reaction with eosinophilia and systemic symptoms300
  • drug hypersensitivity289
  • condition aggravated267
  • pneumonia262
  • diarrhoea255
  • sepsis252
  • hypotension225

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200551
200682
2007150
2008270
200999
201091
2011106
2012152
2013196
2014154
2015265
2016160
2017180
2018265
2019387
2020419
2021628
2022916
2023918
2024771
2025653
2026364

Recalls

2 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,708 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.